Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
... Exelixis Cuts Research Jobs
July 5, 2004
| A version of this story appeared in
Volume 82, Issue 27
Genomics-based drug discovery firm Exelixis will eliminate 62 positions, mostly in research, as part of a restructuring intended to advance drug candidates through clinical development. The cuts, about 11% of Exelixis' workforce, will save at least $10 million annually starting in 2005, according to the firm. "Exelixis has successfully evolved from a research-focused to a product-focused company," CEO George A. Scangos says. The company filed its fourth Investigational New Drug Application with FDA last week.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter